• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Pathophysiological and clinical advances in asthmatic inflammation from the nasopharynx to the peripheral airway in the respiratory tract systems.

作者信息

Koga Yasuhiko, Kamide Yosuke, Hisada Takeshi, Ishizuka Tamotsu

机构信息

Department of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.

Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan.

出版信息

Front Pharmacol. 2023 Jan 16;14:1037610. doi: 10.3389/fphar.2023.1037610. eCollection 2023.

DOI:10.3389/fphar.2023.1037610
PMID:36726579
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9885187/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/9885187/e3d6c9a1dab0/fphar-14-1037610-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/9885187/e3d6c9a1dab0/fphar-14-1037610-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2c0/9885187/e3d6c9a1dab0/fphar-14-1037610-g001.jpg

相似文献

1
Editorial: Pathophysiological and clinical advances in asthmatic inflammation from the nasopharynx to the peripheral airway in the respiratory tract systems.社论：呼吸道系统中从鼻咽到外周气道的哮喘炎症的病理生理与临床进展
Front Pharmacol. 2023 Jan 16;14:1037610. doi: 10.3389/fphar.2023.1037610. eCollection 2023.
2
Omalizumab Restores Response to Corticosteroids in Patients with Eosinophilic Chronic Rhinosinusitis and Severe Asthma.奥马珠单抗可恢复嗜酸性粒细胞性慢性鼻-鼻窦炎合并重度哮喘患者对皮质类固醇的反应。
Biomedicines. 2021 Jul 7;9(7):787. doi: 10.3390/biomedicines9070787.
3
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.生物制剂（贝那利珠单抗、度普利尤单抗、美泊利单抗、奥马珠单抗和瑞利珠单抗）治疗重度嗜酸性粒细胞性哮喘的疗效和安全性。EAACI指南的系统评价——关于生物制剂在重度哮喘中应用的建议
Allergy. 2020 May;75(5):1023-1042. doi: 10.1111/all.14221. Epub 2020 Feb 24.
4
Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.严重哮喘患者的上下气道炎症：精准生物治疗的指导。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620965151. doi: 10.1177/1753466620965151.
5
[A CASE OF SEVERE ASTHMA SWITCHED TO MEPOLIZUMAB DUE TO LATE-OCCURRING UNRESPONSIVENESS TO BENRALIZUMAB].[一例严重哮喘因对贝那利珠单抗出现迟发性无反应而改用美泊利珠单抗的病例]
Arerugi. 2020;69(8):678-682. doi: 10.15036/arerugi.69.678.
6
Rapid and remarkable effectiveness of benralizumab for treating severe bronchial asthma with intractable eosinophilic rhinosinusitis and eosinophilic otitis media: A case report.贝那利珠单抗治疗伴有难治性嗜酸性粒细胞性鼻鼻窦炎和嗜酸性粒细胞性中耳炎的重度支气管哮喘的快速显著疗效：一例报告
Respir Med Case Rep. 2020 Dec 31;32:101336. doi: 10.1016/j.rmcr.2020.101336. eCollection 2021.
7
Comparison of Sinonasal Histopathological Changes in Biological Treatment of Eosinophilic Chronic Rhinosinusitis.比较嗜酸性慢性鼻-鼻窦炎的生物治疗中的鼻-鼻窦组织病理学变化。
Am J Rhinol Allergy. 2022 Jan;36(1):72-80. doi: 10.1177/19458924211021031. Epub 2021 Jun 6.
8
Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy.重度嗜酸性粒细胞性哮喘过敏患者从奥马珠单抗转换为贝那利珠单抗：来自意大利南部的真实病例经验
Biomedicines. 2021 Dec 3;9(12):1822. doi: 10.3390/biomedicines9121822.
9
Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: A case report.使用抗IL-5受体单克隆抗体贝那利珠单抗成功治疗嗜酸性粒细胞性慢性鼻-鼻窦炎和嗜酸性粒细胞性中耳炎：一例报告
Respir Med Case Rep. 2020 Jun 17;30:101135. doi: 10.1016/j.rmcr.2020.101135. eCollection 2020.
10
Asthma Control, Airway Mucus, and Xe MRI Ventilation After a Single Benralizumab Dose.单次 benralizumab 给药后哮喘控制、气道黏液和 Xe MRI 通气。
Chest. 2022 Sep;162(3):520-533. doi: 10.1016/j.chest.2022.03.003. Epub 2022 Mar 10.

本文引用的文献

1
Therapeutical Targets in Allergic Inflammation.过敏性炎症的治疗靶点
Biomedicines. 2022 Nov 9;10(11):2874. doi: 10.3390/biomedicines10112874.
2
Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy.贝那鲁肽治疗伴有严重神经病变的嗜酸性肉芽肿伴多血管炎的长期安全性和疗效。
Intern Med. 2023 May 15;62(10):1553-1556. doi: 10.2169/internalmedicine.0613-22. Epub 2022 Sep 28.
3
Benralizumab: Resolution of Eosinophilic Pulmonary Vasculitis in a Patient With EGPA.
贝那利珠单抗：1例显微镜下多血管炎患者嗜酸性粒细胞性肺血管炎的消退
J Investig Allergol Clin Immunol. 2021 Dec;31(6):519-521. doi: 10.18176/jiaci.0689.
4
Higher Risk of Hyperthyroidism in People with Asthma: Evidence from a Nationwide, Population-Based Cohort Study.哮喘患者患甲状腺功能亢进症的风险更高：一项基于全国人群的队列研究证据
J Allergy Clin Immunol Pract. 2022 Mar;10(3):751-758.e1. doi: 10.1016/j.jaip.2021.09.021. Epub 2021 Sep 23.
5
Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms.二甲双胍与纤维化：现有证据与作用机制的综述。
J Diabetes Res. 2021 Apr 29;2021:6673525. doi: 10.1155/2021/6673525. eCollection 2021.
6
Metformin alleviates allergic airway inflammation and increases Treg cells in obese asthma.二甲双胍可缓解肥胖型哮喘的气道炎症过敏反应，并增加 Treg 细胞。
J Cell Mol Med. 2021 Feb;25(4):2279-2284. doi: 10.1111/jcmm.16269. Epub 2021 Jan 9.
7
Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis.贝那利珠单抗对嗜酸性肉芽肿性多血管炎患者的激素节省作用。
ERJ Open Res. 2020 Nov 10;6(4). doi: 10.1183/23120541.00451-2020. eCollection 2020 Oct.
8
[Research progress of non-coding RNA in regulating the function of T cells in asthma].非编码RNA在调节哮喘中T细胞功能方面的研究进展
Sheng Li Xue Bao. 2020 Oct 25;72(5):586-596.
9
Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis.贝那利珠单抗作为嗜酸性肉芽肿性多血管炎严重哮喘的糖皮质激素节省治疗选择。
J Allergy Clin Immunol Pract. 2020 Oct;8(9):3225-3227.e2. doi: 10.1016/j.jaip.2020.05.033. Epub 2020 Jun 4.
10
Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis.早期使用贝那利珠单抗治疗嗜酸性肉芽肿性多血管炎合并嗜酸性粒细胞性心肌炎。
Allergol Int. 2020 Jul;69(3):483-484. doi: 10.1016/j.alit.2020.03.001. Epub 2020 Mar 27.